Retzius-sparing robot-assisted laparoscopic radical prostatectomy for early-stage prostate cancer (with video).
- Author:
Hong-Qian GUO
1
;
Xiao-Gong LI
1
;
Wei-Dong GAN
1
;
Gu-Tian ZHANG
1
;
Lin-Feng XU
1
;
Feng QU
1
;
Xiao-Zhi ZHAO
1
;
Lin-Fang YAO
1
;
Shi-Wei ZHANG
2
Author Information
1. Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China.
2. .
- Publication Type:Journal Article
- Keywords:
Retzius-sparing;
laparoscopy;
prostate cancer;
radical prostatectomy;
robot surgical system
- MeSH:
Blood Loss, Surgical;
Humans;
Laparoscopy;
methods;
Length of Stay;
Male;
Margins of Excision;
Middle Aged;
Operative Time;
Postoperative Period;
Prostatectomy;
methods;
Prostatic Neoplasms;
pathology;
surgery;
Retrospective Studies;
Robotic Surgical Procedures
- From:
National Journal of Andrology
2017;23(1):34-38
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the application of Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) in the treatment of early-stage prostate cancer.
METHODS:We retrospectively analyzed the clinical data about 10 cases of early-stage prostate cancer treated by RS-RARP with the Da Vinci Robot Surgical System from September to October 2016.
RESULTS:All the operations were successfully completed without positive surgical margins. The operation time was 170－250 min (［196±25］ min), the intraoperative blood loss was 150－500 ml (［260±128］ ml), the postoperative hospital stay was 6－7 days, and the catheterization time was 14 days. Urinary continence occurred after catheter removal in 1 patient and was recovered 1 month later.
CONCLUSIONS:RS-RARP is a safe, effective and reliable method for the treatment of prostate cancer and conducive to the early recovery of urinary continence.
